Currently, the human epidermal growth factor receptor 2 (HER2) status of breast cancer is classified dichotomously as negative or positive to select patients for HER2-targeted therapy. However, with the introduction of novel treatment options, it is important to get more insight in the biology of...
Triple-negative breast cancer (TNBC) has a worse prognosis compared with other breast cancer subtypes, and biomarkers to identify patients at high risk of recurrence are needed. Here, we investigated the expression of human epidermal receptor (HER) family members in TNBC and evaluated their potentia...
These include tissues fixed in fixatives other than neutral-buffered formalin, needle core biopsies fixed in formalin for less than 1 h, excisional biopsies fixed in formalin for less than 6 h, and any specimen fixed in formalin longer than 48 h. However, these are not ‘absolute’ ...
This study aimed to explore potential indicators associated with the neoadjuvant efficacy of TCbHP regimen (taxane, carboplatin, trastuzumab, and pertuzumab) in HER2 + breast cancer (BrCa) patients. A total of 120 plasma samples from 40 patients wi
CD10/CALLA (Neutral Endopeptidase) CD10抗原进口/国产 规格: 0.5mg ZCWCC1(Zinc finger CW-type coiled-coil domain protein 1) ZCWCC1抗原 现货供应 规格: 0.5mg CD105/Endoglin/TGF- Beta receptor CD105/转化生长因子β受体抗原特价促销 规格: 0.5mg ...
Approximately one in five breast cancers are driven by amplification and overexpression of the human epidermal growth factor receptor 2 (HER2) receptor kinase, and HER2-enriched (HER2E) is one of four major transcriptional subtypes of breast cancer. We s
Patritumab deruxtecan (HER3-DXd) exhibits promising efficacy in breast cancer, with its activity not directly correlated to baseline ERBB3/HER3 levels. This research investigates the genetic factors affecting HER3-DXd’s response in women with early-stag
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Supplementary information Supplementary Information Rights and permissions Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this...
The p53-positive patients were more likely to achieve tpCR and bpCR than p53-negative patients (P < 0.05). The incidence of hypokalemia and diarrhea in the case group was higher than that in the control group (P < 0.05). The AEs developed were all manageable, and no treatment...
Growing evidence suggests a clear role of the host immune system in HER2+ breast cancer. In addition, HER2+ breast cancer is generally considered more immunogenic than hormone receptor-positive (HR+)/HER2-, and specific molecular HER2+ subgroups (e.g. HE